Table 1.

Characteristics of five patients diagnosed with pheochromocytoma/paraganglioma treated with PRRT.

Case	Diagnosis	Sites of Metastasis	Functional Symptoms	Day 1, Cycle 1 Symptom Management Medications *	PRRT Infusion Reactions
Case 1	28 y.o. male, left adrenal pheo age 24, recurred age 25.	Bone, nodal, >75% liver, lung	Severe weight loss, uncontrolled HTN, tachy.	Doxazosin 8 mg po bid. Nifedipine 30 mg ER po tid. Propranolol 120 mg ER po qd	No reactions NOTE: Due to uncontrolled baseline hypertension, IV calcium channel blocker therapy was given during cycle
Case 2	28 y.o. male, right adrenal pheo age 25, recurred age 27.	Bone, nodal, liver, lung	Severe weight loss, HTN, tachy, constipation, anxiety, palpitations.	Prazosin 2 mg qd (held after cycle 3) Metoprolol 25 mg extended release BID (held after cycle 3)	None
Case 3	45 y.o. male, right pelvic mass and adenopathy, para on biopsy.	Soft tissue pelvic mass, hydronephrosis and nodes	Severe weight loss, tachy, night sweats, HTN.	Prazosin 2 mg PO BID Atenolol 25 mg PO once daily (held after cycle 2)	None
Case 4	52 y.o. female, SDHB mut, age 21 left adrenal pheo, relapsed age 51 with spinal metastases.	L3–L5, thoracic node	Tachy	Doxazosin 2 mg PO BID (held after cycle 4) Atenolol 12.5 mg PO once daily (held after cycle 1)	None
Case 5	61 y.o. male, germline SDHB mut, carotid body para age stable over 31 years, transformed to rapidly progressive at age 61.	Carotid artery invasion and regional nodes	None	None	None

Abbreviations: y.o.: years old; Pheo: pheochromocytoma; Para: paraganglioma; HTN: hypertension; tachy: tachycardia; mut: mutation. * Pre-medications were started several weeks prior to scheduled PRRT treatment, with target blood pressure <120/80 mmHg.